Literature DB >> 16098078

Genotype-phenotype correlation in MYH9-related thrombocytopenia.

Fan Dong1, Sufeng Li, Núria Pujol-Moix, Naomi L C Luban, Sang Won Shin, Jae Hong Seo, Arlette Ruiz-Saez, Judit Demeter, Scott Langdon, Michael J Kelley.   

Abstract

Mutation of the non-muscle myosin heavy chain type II-A results in MYH9-related hereditary macrothrombocytopenia (HMTC), including four autosomal dominant platelet disorders: May-Hegglin anomaly (MHA), Sebastian (SBS), Fechtner (FS) and Epstein (EPS) syndrome. Denaturing high-performance liquid chromatography (DHPLC) was optimised for rapid screening of the seven exons harbouring all but one of the previously reported mutations of MYH9. Individuals from 13 families with phenotypes suggestive of MYH9-related HMTC were screened for mutations by DHPLC followed by direct sequencing of samples with aberrant column retention time. Mutations were identified in all 13 families. Six distinct missense heterozygous mutations were found in 10 families, including six families with MHA or SBS (E1841K, D1424N), three families with FS (R702H, R1165C, and D1424Y), and one family with EPS (S96L). A truncating mutation (R1933X) was found in three MHA families. A review of all published mutations suggests that mutation in the C-terminal coiled coil region or truncation of the tailpiece is associated with haematological-only phenotype, while mutation of the head ATPase domain frequently is associated with nephropathy and/or hearing loss. Mutations of other regions have intermediate expression of non-haematological characteristics. Further study is required to confirm these associations and understand the molecular basis for this genotype-phenotype relationship.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098078     DOI: 10.1111/j.1365-2141.2005.05658.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Authors:  Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

2.  Clinical application of a custom AmpliSeq library and ion torrent PGM sequencing to comprehensive mutation screening for deafness genes.

Authors:  Shin-Ya Nishio; Yoshiharu Hayashi; Manabu Watanabe; Shin-Ichi Usami
Journal:  Genet Test Mol Biomarkers       Date:  2015-01-14

3.  Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.

Authors:  Keri B Sanborn; Emily M Mace; Gregory D Rak; Analisa Difeo; John A Martignetti; Alessandro Pecci; James B Bussel; Rémi Favier; Jordan S Orange
Journal:  Blood       Date:  2011-11-24       Impact factor: 22.113

Review 4.  MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.

Authors:  Alessandro Pecci; Xuefei Ma; Anna Savoia; Robert S Adelstein
Journal:  Gene       Date:  2018-04-19       Impact factor: 3.688

Review 5.  Pathogenesis and therapy of focal segmental glomerulosclerosis: an update.

Authors:  Rasheed Gbadegesin; Peter Lavin; John Foreman; Michelle Winn
Journal:  Pediatr Nephrol       Date:  2010-11-26       Impact factor: 3.714

Review 6.  Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.

Authors:  Zygimantas C Alsauskas; Raj Kiran Medapalli; Michael J Ross
Journal:  Expert Opin Pharmacother       Date:  2011-01-21       Impact factor: 3.889

7.  [Therapy-refractory thrombocytopenia in a 28-year-old patient].

Authors:  D Sauter; H Ostermann; K Selleng; K Spiekermann
Journal:  Internist (Berl)       Date:  2011-02       Impact factor: 0.743

8.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

Authors:  Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 9.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

10.  MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury and Migration.

Authors:  Sylvia Cechova; Fan Dong; Fang Chan; Michael J Kelley; Phillip Ruiz; Thu H Le
Journal:  J Am Soc Nephrol       Date:  2017-10-09       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.